Us Bancorp \De\ Cyma Bay Therapeutics, Inc. Transaction History

Us Bancorp \De\

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$12.63 - $24.47 $202,976 - $393,257	-16,071 Reduced 35.67%	28,986 $684,000
Q3 2023 Nov 03, 2023	BUY	$10.86 - $17.62 $489,319 - $793,904	45,057 New	45,057 $671,000
Q1 2023 May 09, 2023	BUY	$5.88 - $9.59 $2,116 - $3,452	360 New	360 $3,000
Q1 2021 Apr 28, 2021	SELL	$4.23 - $6.55 $5,638 - $8,731	-1,333 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$5.73 - $9.03 $7,638 - $12,036	1,333 New	1,333 $8,000
Q2 2019 Aug 13, 2019	SELL	$6.05 - $13.66 $3,025 - $6,830	-500 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$6.54 - $11.74 $3,270 - $5,870	500 New	500 $4,000
Q3 2018 Nov 01, 2018	SELL	$10.88 - $14.52 $5,440 - $7,260	-500 Closed	0 $0
Q2 2018 Aug 08, 2018	BUY	$10.66 - $14.38 $5,330 - $7,190	500 New	500 $7,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.